# Test Results

**Oncology BCR/ABL1 FISH**

<table>
<thead>
<tr>
<th>Test Description</th>
<th>Result</th>
<th>Flag</th>
<th>Units</th>
<th>Reference Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specimen Type</td>
<td></td>
<td>01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cells Counted</td>
<td>200</td>
<td>01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cells Analyzed</td>
<td>200</td>
<td>01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FISH Result</td>
<td></td>
<td>01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interpretation</td>
<td></td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Comment:**

The fluorescence in situ hybridization (FISH) study was negative. FISH, using unique sequence DNA probes for the ABL1 and BCR gene regions showed two normal ABL1 signals (red), two control ASS1 (Argininosuccinate Synthetase) gene signals (aqua) located adjacent to the ABL1 locus at 9q34, and two normal BCR signals (green) at 22q11.2 in all 200 interphase nuclei examined. There was NO evidence of CML or ALL-associated BCR/ABL1 dual fusion signals in this analysis.

Chromosome analysis should be considered to identify clonal alterations not targeted by the FISH probes ordered. FISH results should be interpreted within the context of a full hematopathology evaluation.

This test was developed and its performance characteristics determined by Laboratory Corporation of America Holdings (LabCorp). It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.
<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>YU</td>
<td>LabCorp RTP</td>
<td>Dir: Arundhati Chatterjee, MD</td>
<td>1904 TW Alexander Drive Suite C, RTP, NC 27709-0153</td>
<td></td>
</tr>
</tbody>
</table>

For inquiries, the physician may contact Branch: 800-222-7566  Lab: 800-735-4087
Client/Sending Facility:
LabCorp Test Master
Test Account
3060 South Church Street
Burlington, NC 27215
Ph: (336)436-8645
POE-00

LCLS Specimen Number: 238-225-9017-0
Patient Name: SAMPLE REPORT, 511520
Date of Birth: 12/15/1952
Gender: F
Patient ID:
Lab Number: YU16-67594 F
Indications:

Test: Oncology BCR/ABL1 FISH

Cells Counted: 200
Cells Analyzed: 200

FISH RESULT: NORMAL: NO BCR OR ABL GENE REARRANGEMENT OBSERVED

INTERPRETATION:

nuc ish 9q34 (ASS1, ABL1) x2, 22q11.2 (BCRx2) [200]

The fluorescence in situ hybridization (FISH) study was negative. FISH, using unique sequence DNA probes for the ABL1 and BCR gene regions showed two normal ABL1 signals (red), two control ASS1 (Argininosuccinate Synthetase) gene signals (aqua) located adjacent to the ABL1 locus at 9q34, and two normal BCR signals (green) at 22q11.2 in all 200 interphase nuclei examined. There was NO evidence of CML or ALL-associated BCR/ABL1 dual fusion signals in this analysis.

Chromosome analysis should be considered to identify clonal alterations not targeted by the FISH probes ordered. **FISH results should be interpreted within the context of a full hematopathology evaluation.**

This test was developed and its performance characteristics determined by Laboratory Corporation of America Holdings (LabCorp). It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.

M. Katharine Rudd, PhD, FACMG
Board Certified Cytogeneticist

Arundhati Chatterjee, MD
Medical Director

Peter Papenhausen, PhD
National Director of Cytogenetics

Professional Component performed by LabCorp CLIA 34D1008914, 1904 TW Alexander Dr, Research Triangle Park, NC 27709. Medical Director, Arundhati Chatterjee, MD. Integrated Oncology is a brand used by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of Laboratory Corporation of America Holdings.

This document contains private and confidential health information protected by state and federal law.
Oncology BCR/ABL1 FISH

**Specimen Type:** Comment: 01
- **Bone Marrow**

**Cells Counted:** 200 01
**Cells Analyzed:** 200 01
**FISH Result:** Comment: 01
- **ABNORMAL: 50% OF NUCLEI POSITIVE FOR BCR/ABL GENE FUSION SIGNALS**

**Interpretation:** Comment: 01
- **CML/ALL RELATED CLONE DETECTED**

**nuc ish 9q34 (ABL1x3, ASSx2), 22q11.2 (BCRx3) (ABL1 con BCRx2) [100/200]**

The fluorescence in situ hybridization (FISH) study on the sample received was positive for the BCR/ABL gene fusion. Unique sequence dual fusion DNA probes for the BCR (22q11.2) and ABL1 (9q34) loci and a control gene, ASS (Argininosuccinate Synthetase) located adjacent to ABL1 showed two BCR/ABL1 fusion signals, a single ABL1 signal and a single BCR signal in all abnormal interphase cells analyzed. The presence of BCR/ABL1 fusion signals is associated with the Philadelphia translocation, the hallmark of CML, as well as ALL.

In those cases where blood is submitted for BCR/ABL FISH, the results should be interpreted in conjunction with PMN ratios.

Chromosome analysis should be considered to identify clonal alterations not targeted by the FISH probes ordered. FISH results should be interpreted within the context of a full hematopathology evaluation.

*This test was developed and its performance characteristics determined by Laboratory Corporation of America Holdings*
(LabCorp). It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.

Director Review: M. Katharine Rudd, PhD, FACMG

For inquiries, the physician may contact Branch: 800−222−7566 Lab: 800−735−4087
LCLS Specimen Number: 238-225-9018-0
Patient Name: SAMPLE REPORT, 511520
Date of Birth: 10/11/2000
Gender: F
Patient ID: 
Lab Number: YU16-67604 F

Indications:

Test: Oncology BCR/ABL1 FISH

Cells Counted: 200

Cells Analyzed: 200

FISH RESULT: ABNORMAL: 50% OF NUCLEI POSITIVE FOR BCR/ABL GENE FUSION SIGNALS

INTERPRETATION: CML/ALL RELATED CLONE DETECTED

nuc ish 9q34 (ABL1x3, ASSx2), 22q11.2 (BCRx3) (ABL1 con BCRx2) [100/200]

The fluorescence in situ hybridization (FISH) study on the sample received was positive for the BCR/ABL1 gene fusion. Unique sequence dual fusion DNA probes for the BCR (22q11.2) and ABL1 (9q34) loci and a control gene, ASS (Argininosuccinate Synthetase) located adjacent to ABL1 showed two BCR/ABL1 fusion signals, a single ABL1 signal and a single BCR signal in all abnormal interphase cells analyzed. The presence of BCR/ABL1 fusion signals is associated with the Philadelphia translocation, the hallmark of CML, as well as ALL.

In those cases where blood is submitted for BCR/ABL FISH, the results should be interpreted in conjunction with PMN ratios.

Chromosome analysis should be considered to identify clonal alterations not targeted by the FISH probes ordered. FISH results should be interpreted within the context of a full hematopathology evaluation.

This test was developed and its performance characteristics determined by Laboratory Corporation of America Holdings (LabCorp). It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.
LCLS Specimen Number: 238-225-9018-0
Patient Name: SAMPLE REPORT, 511520
Date of Birth: 10/11/2000
Gender: F
Patient ID: 
Lab Number: YU16-67604  F

Account Number: 90000999
Ordering Physician:
Specimen Type: BONE MARROW
Client Reference:
Date Collected: 08/25/2016
Date Received: 08/26/2016

M. Katharine Rudd, PhD, FACMG
Board Certified Cytogeneticist

Arundhati Chatterjee, MD
Medical Director
Peter Papenhausen, PhD
National Director of Cytogenetics

Technical component performed by Laboratory Corporation of America Holdings, 1904 TW Alexander Drive, RTP, NC, 27709-0153 (800) 345-4363

Professional Component performed by LabCorp CLIA 34D1008914, 1904 TW Alexander Dr, Research Triangle Park, NC 27709. Medical Director, Arundhati Chatterjee, MD. Integrated Oncology is a brand used by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of Laboratory Corporation of America Holdings.

This document contains private and confidential health information protected by state and federal law.